KX01 is an inhaled anti-inflammatory treatment for patients developing Bronchiolitis Obliterans Syndrome (BOS) after lung transplant and allogenic stem cell transplant. Currently, no treatments are approved by FDA.
KX01 have showed to address inflammation, fibrosis, and vasculopathy with the potential to prevent and treat and prevent chronic lung allograft dysfunction (CLAD) in lung transplantation patients.
Reducing disease burden for patients with interstitial lung diseases
KX03 is an inhaled treatment for patients with fibrotic lung diseases.
KX03 has the potential to reduce disease burden and improve quality of life in patients with idiopathic pulmonary fibrosis.